News & Press Releases

In the early stages of Parkinson’s disease, alpha-synuclein accumulates in the brain, damaging nerve cells that produce dopamine. Dopamine is a hormone that regulates movement. Its absence in the brain can cause movement problems, among other symptoms.

LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio’s (NYSE: ANVS) recent feature on Today’s Marketplace (TMP) as part of its commitment to amplifying industry leaders’ voices through targeted distribution channels.

Annovis Bio (NYSE: ANVS), a leader in developing treatments for neurodegenerative diseases, was recently featured on Today’s Marketplace in an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO. Dr. Maccecchini detailed Annovis Bio’s groundbreaking drug development targeting toxic proteins responsible for nerve cell damage in Alzheimer’s and Parkinson’s, as well as the company’s next-phase clinical trials. Emphasizing the broader impact of these diseases on caregivers as well as patients, Dr. Maccecchini shared insights into the meaningful progress Annovis Bio is making. The Today’s Marketplace feature continues to spotlight Annovis Bio’s leadership in addressing critical healthcare challenges, reinforcing its commitment to innovation and improving lives.

Annovis Bio (NYSE: ANVS) was featured in an interview with Today’s Marketplace (“TMP”). The company’s Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University’s Institute for Population Health, joined host Jane King to discuss clinical trials of a new drug that is showing promise for the treatment of neurodegenerative diseases like Alzheimer’s (“AD”) and Parkinson’s (“PD”) and their impact on population health.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a live investor webcast on Dec. 11, 2024, at 4:30 p.m. EST, to provide key operational highlights and year-end clinical updates ( https://ibn.fm/69VpQ ).

Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria Maccecchini, the event will highlight updates on Phase 3 studies for Parkinson’s and Alzheimer’s diseases, regulatory milestones, financial strategies, and plans for advancing neurodegenerative therapies in 2025.

Alzheimer’s and cancer are common diagnoses, especially among older individuals. Prior research has observed an inverse association between both conditions, with a separate study also finding that survivors of cancer have a lower risk of developing Alzheimer’s in comparison to individuals without a history of cancer.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently achieved a significant milestone in its drug development process. In early October, the company held a meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), concluded the third quarter with significant milestones achieved and a clear path forward for its lead candidate, buntanetap.

Annovis Bio (NYSE: ANVS) announced that its President and CEO, Dr. Maria Maccecchini, will speak at the National Institute on Aging’s (NIA) workshop, “Dementia with Lewy Bodies: Filling the Gaps in Translational and Clinical Research.” Scheduled for Nov. 13, 2024, Dr. Maccecchini’s presentation, titled “One Drug, Dual Effect: Buntanetap Improves Cognitive and Motor Functions, Benefiting Alzheimer’s and Parkinson’s Patients. A Potential Path for Lewy Body Dementia?” will explore the potential of Annovis’s lead drug candidate, Buntanetap, to address neurodegenerative diseases by enhancing cognitive and motor functions, with implications for Lewy body dementia treatment.

Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial to evaluate symptomatic relief and an 18-month trial to assess disease-modifying potential, with the first study slated to start in Q1 2025. Financially, the company raised $12.7 million through its equity line of credit and $7.1 million from warrant exercises, securing its runway to enter Phase 3 trials. Annovis also strengthened its intellectual property with new patents for buntanetap combination therapies and expanded its team with the appointment of Senior Clinical Scientist Dr. Matthew Peterson to support trial quality and completion.

Annovis Bio (NYSE: ANVS) has appointed Dr. Matthew Peterson as Senior Clinical Scientist, bolstering the team as it approaches pivotal Phase 3 trials for its neurodegenerative disease therapies, including treatments for Alzheimer’s and Parkinson’s disease. Dr. Peterson, an experienced clinical researcher with a background in both academic and industry roles, joins from Axogen, where he specialized in therapies for peripheral nerve repair. With expertise in enhancing patient care and research experience with the Department of Veterans Affairs, he will focus on ensuring the scientific rigor and success of Annovis’ clinical trials for its lead drug candidate, buntanetap.

Annovis (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), presented two scientific posters at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference ( https://ibn.fm/ysPFn ), held between Oct. 29 and Nov. 1 in Marid, Spain.

A new study has investigated how exposure to antimicrobials influences the risk of Parkinson’s disease development. Parkinson’s disease is a brain disorder that affects an individual’s movement, causing stiffness, tremors as well as issues with coordination and balance.

Annovis Bio (NYSE: ANVS) led by Founder, President and CEO Dr. Maria Maccecchini, shares exciting developments regarding its pioneering Alzheimer’s and Parkinson’s drug candidate, buntanetap. In her interview on IBN’s BioMedWire Podcast, Dr. Maccecchini discusses Annovis Bio’s recent FDA clearance to proceed with pivotal Phase 3 trials for early-stage Alzheimer’s patients, a critical step toward potential market approval. Highlighting buntanetap’s unique mechanism that targets multiple neurotoxic proteins, Dr. Maccecchini explains the potential for superior outcomes compared to existing therapies, emphasizing the drug’s demonstrated short-term efficacy and differentiated approach in neurodegenerative treatment.

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering novel therapies for neurodegenerative diseases. Recent clinical trials of the company’s lead compound yielded encouraging results, with buntanetap shown to improve cognition in both Alzheimer’s and Parkinson’s patients. The company also introduced a new crystalline form of buntanetap with improved properties, “offering significant advantages over the less structured, old semi-crystalline form,” according to a recent article.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently announced a significant milestone in its drug development process. On October 10, 2024, the company held an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap.

Annovis Bio (NYSE: ANVS) will showcase its latest scientific findings on its Alzheimer’s drug candidate, Buntanetap, at the 17th Clinical Trials on Alzheimer’s Disease (“CTAD”) conference in Madrid from Oct. 29 to Nov. 1, 2024. The company will present two posters highlighting Buntanetap’s efficacy in early Alzheimer’s patients and its impact on reducing neurotoxic proteins, improving axonal integrity, and enhancing neuronal function. These results further support Annovis Bio’s ongoing efforts to develop transformative therapies for neurodegenerative diseases.

New research has observed that serious viral infections, including pneumonia and encephalitis, heighten the risk of neurodegenerative illnesses such as Alzheimer’s and Parkinson’s. This comes after previous research found a connection between the Epstein-Barr virus and a heightened risk of developing multiple sclerosis.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), announced today that the U.S. Food and Drug Administration (“FDA”) has granted clearance to proceed with pivotal Phase 3 studies for buntanetap in early-stage Alzheimer’s patients. This decision follows a successful End-of-Phase 2 meeting held on Oct. 10, 2024, where Annovis and the FDA aligned on the next steps for advancing buntanetap toward New Drug Application (“NDA”) submissions.

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently filed three new patents ( https://ibn.fm/wWksA ). The patent applications seek protection for innovative combination therapies involving buntanetap that improve cognition beyond normal levels.

NetworkNewsWire Editorial Coverage : Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer’s disease (“AD”) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (“FDA”) approvals of Leqembi and Kisunla — although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like peptide-1 (“GLP-1”) and phosphodiesterase 5 (“PDE5”) inhibitor drugs show promise in treating Alzheimer’s, with companies such as Annovis Bio Inc. (NYSE: ANVS) ( profile ) leading the way with treatments ready for late-stage clinical trials. Beyond Alzheimer’s, the pharmaceutical industry is experiencing a surge of innovation across various disease areas. Major players, including Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS) , Merck & Co. Inc. (NYSE: MRK) and GSK plc (NYSE: GSK) are at the forefront of medical innovation, tackling…

EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END

NetworkNewsWire Editorial Coverage : Alzheimer’s disease (“AD”) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (“FDA”) approval. However, while these treatments may slow cognitive decline in AD patients, they do not actually improve cognition, a critical target for the millions suffering from the progressive disease. In addition, GLP-1 (glucagon-like peptide-1) drugs, which were originally developed to manage type 2 diabetes and since have seen significant effectiveness in treating obesity, have also shown potential in the treatment of Alzheimer’s. However, there is no molecule or a combination of molecules that enhance cognitive functions. Thanks to innovative approaches by companies such as Annovis Bio Inc. (NYSE: ANVS) ( profile ), there is reason to be optimistic about potential future breakthroughs in the AD space. Annovis has completed early research with compelling results utilizing its lead drug, buntanetap, in combination with popular drugs approved for other indications. Broadly speaking, there is ample reason to be bullish on new treatments for a variety of significant diseases, including AD and obesity, as companies such as Eli Lilly (NYSE: LLY) , Pfizer Inc. (NYSE: PFE) , Novo Nordisk (NYSE: NVO) and AbbVie Inc. (NASDAQ: ABBV) are making investments and progress on historically…

EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END